Portmanteau inhibitor

A portmanteau inhibitor is a drug that is a combination of two drug molecules, each of which is itself a type of inhibitor. The term was coined in 2007 by University of Minnesota researchers who designed and synthesized a combination HIV reverse transcriptase inhibitor and an integrase inhibitor,{{cite web|url=http://www.kare11.com/news/news_article.aspx?storyid=260376|title= U of M researchers announce advance in treatment of HIV|date=25 July 2007|access-date=25 July 2007}}{{cite web|url=https://www.sciencedaily.com/releases/2007/07/070723160034.htm|title=Researchers Discover New Method To Combat HIV|date=25 July 2007|access-date=25 July 2007}}{{cite journal|pmid=17608468|title=Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase|author1 =Zhengqiang Wang|author2 =Eric M. Bennett|author3 =Daniel J. Wilson|author4 =Christine Salomon|author5 = Robert Vince |author-link5 = Robert Vince (scientist) |journal=Journal of Medicinal Chemistry|year=2007|volume=50|issue=15|pages=3416–3419|doi=10.1021/jm070512p|citeseerx=10.1.1.535.8472}} and was further used in 2011 by a team of researchers combining an integrase inhibitor with a CCR5 entry inhibitor.{{Cite journal | last1 = Bodiwala | first1 = H. S. | last2 = Sabde | first2 = S. | last3 = Gupta | first3 = P. | last4 = Mukherjee | first4 = R. | last5 = Kumar | first5 = R. | last6 = Garg | first6 = P. | last7 = Bhutani | first7 = K. K. | last8 = Mitra | first8 = D. | last9 = Singh | first9 = I. P. | doi = 10.1016/j.bmc.2010.12.031 | title = Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5 | journal = Bioorganic & Medicinal Chemistry | volume = 19 | issue = 3 | pages = 1256–63 | year = 2011 | pmid = 21227704}}